Document is current
Any future updates will be listed below
-
Authors
Andreou, Chrysafis http://orcid.org/0000-0002-3464-9110
Weissleder, Ralph http://orcid.org/0000-0003-0828-4143
Kircher, Moritz F. http://orcid.org/0000-0003-1575-1467
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R33CA202064, UH2CA202637, RO1CA204019, RO1CA206890, UO1CA206997, R01EB017748, R01CA222836)
Pershing Square Foundation
Parker Institute for Cancer Immunotherapy
- License Information
-
More Information
Article History
Received: 30 January 2019
Accepted: 6 September 2021
First Online: 27 May 2022
Competing interests
: R.W. has received consultancy payments from ModeRNA, Tarveda Pharmaceuticals, Alivio Therapeutics and Accure Health, and is a shareholder of T2Biosystems, Lumicell and Accure Health. All patents associated with R.W. have been assigned to and are handled by the Massachusetts General Hospital. M.F.K is a co-founder of RIO Imaging, which did not contribute to this manuscript. All patents associated with M.F.K. have been assigned to and are handled by Stanford University or Memorial Sloan Kettering Cancer Center, respectively. C.A. declares no competing interests.
